(Q37750274)

22 August 2017

1 reference

title

Managing type 2 diabetes: balancing HbA1c and body weight (English)

1 reference

22 August 2017

0 references

Annie A Mavian

1

1 reference

22 August 2017

Stephan Miller

series ordinal

2

1 reference

22 August 2017

Robert R Henry

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 May 2010

1 reference

22 August 2017

Postgraduate Medicine

1 reference

22 August 2017

122

1 reference

22 August 2017

3

1 reference

22 August 2017

106-117

1 reference

Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006

22 August 2017

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Prevalence and trends in obesity among US adults, 1999-2008

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Pleiotropic effects of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Effect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

The combination of insulin and metformin in treatment of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Beyond glycemic control: treating the entire type 2 diabetes disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3810%2FPGM.2010.05.2148

21 January 2018

Identifiers

DOI

10.3810/PGM.2010.05.2148

1 reference

22 August 2017

1 reference